Have you been diagnosed with metastatic castration-resistant prostate cancer? If so, you may be eligible for a research study to help find out if combining two investigational drugs, called niraparib and JNJ-63723283, is effective as a treatment for metastatic prostate cancer. Reimbursement provided for travel and meals for each visit.
IRB:6137-LJAppleman - A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
MEET THE RESEARCHER
Leonard J. Appleman, MD, PhD, is an Associate Professor of Medicine in the Division of Hematology/Oncology. A graduate of New York University School of Medicine, Dr. Appleman’s research interests include the development of novel therapeutics for kidney cancer, prostate cancer, and other malignancies.